Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: is PTEN predictive of response?

Glioblastoma (GBM) is fatal. The standard radiotherapy and chemotherapy (temozolomide) followed by an adjuvant phase of temozolomide provide patients with, on average, a 2.5 months benefit. New treatments that can improve sensitivity to the standard treatment are urgently needed. Herein, we review the mechanisms and utility of poly (ADP-ribose) polymerase inhibitors in combination with radiation therapy as a treatment option for GBM patients and the role of phosphatase and tensin homologue mutations as a biomarker of response (AU9

No disponible

Cuando la resistencia a los bloqueadores del receptor de adenosindifosfato centra toda la atención, ¿la resistencia a la aspirina tiene algo que decir? / With so much attention paid to adenosine diphosphate receptor blockers, is there still a role for aspirin resistance?

No disponible